Again if we get similar results like those in MS trial then this...

Again if we get similar results like those in MS trial then this stock will be unstoppable .......


DMD has similar disease features to multiple sclerosis (MS), which was the company’sinitial focus and still hopes to pursue.
Antisense has completed phase II studies for acromegaly and MS and has ethics approval for a local phase II trial pertaining to DMD.With ATL1102, Antisense targeted patients with relapsing remitting MS (ATL1102 is an antisense inhibitor of the VLA-4 protein a recognised MS target).The MS trial produced evidence that the drug “significantly reduced the number of brain lesions in patients with relapsing-remitting MS”.The trial met the primary endpoint with a 54.4 percent reduction in the cumulative number of new active brain lesions (compared with placebo).

Dr Bill Goolsbee was chairman of the Nasdaq-listed immunotherapy house Sarepta Therapeutics and is a key part of the Antisense story.In 2016, Sarepta went from a $US50 million market cap when it gained FDA approval for its Exondys 51 DMD drug (which has a different mechanism of action from ATL-1102) and is now worth $US6 billion